TY - JOUR
T1 - A phase I‐II trial of the combination of recombinant leukocyte a interferon and recombinant human interferon‐γ in patients with metastatic malignant melanoma
AU - Creagan, Edward T.
AU - Loprinzi, Charles L.
AU - Ahmann, David L.
AU - Schaid, Daniel J.
PY - 1988/12/15
Y1 - 1988/12/15
N2 - Twenty patients with advanced malignant melanoma received daily intramuscular recombinant leukocyte A interferon (rIFN‐αA, Roferon‐A, Hoffmann‐Laroche, Nutley, NJ) concomitant with recombinant human interferon‐γ (rIFN‐γ Genentech, South San Francisco, CA). During the first week or dose was 2 × 106 U/m2 and the γ dose was 0.01 mg/m2 with escalations, if clinically tolerable, during the second week to 5 × 106 U/m2 and 0.025 mg/m2, respectively. Twelve patients received the escalated doses; subsequent granulocytopenia and a flu‐type illness were severe in four of the 12. We observed one partial response of MRI‐documented and biopsy‐confirmed osseous metastases for 7+ months. For all study participants, the median time to progression was 1 month with a median survival of 6 months. From the dose and schedule which we utilized, concurrent rIFN‐αA and rIFN‐γ provided little impact on advanced malignant melanoma.
AB - Twenty patients with advanced malignant melanoma received daily intramuscular recombinant leukocyte A interferon (rIFN‐αA, Roferon‐A, Hoffmann‐Laroche, Nutley, NJ) concomitant with recombinant human interferon‐γ (rIFN‐γ Genentech, South San Francisco, CA). During the first week or dose was 2 × 106 U/m2 and the γ dose was 0.01 mg/m2 with escalations, if clinically tolerable, during the second week to 5 × 106 U/m2 and 0.025 mg/m2, respectively. Twelve patients received the escalated doses; subsequent granulocytopenia and a flu‐type illness were severe in four of the 12. We observed one partial response of MRI‐documented and biopsy‐confirmed osseous metastases for 7+ months. For all study participants, the median time to progression was 1 month with a median survival of 6 months. From the dose and schedule which we utilized, concurrent rIFN‐αA and rIFN‐γ provided little impact on advanced malignant melanoma.
UR - http://www.scopus.com/inward/record.url?scp=0024203369&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024203369&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19881215)62:12<2472::AID-CNCR2820621203>3.0.CO;2-G
DO - 10.1002/1097-0142(19881215)62:12<2472::AID-CNCR2820621203>3.0.CO;2-G
M3 - Article
C2 - 3142675
AN - SCOPUS:0024203369
SN - 0008-543X
VL - 62
SP - 2472
EP - 2474
JO - Cancer
JF - Cancer
IS - 12
ER -